



Treating Diarrhea in Your Dog Undergoing Chemotherapy



A dog owner's guide to the treatment of chemotherapy-induced diarrhea (CID) with Canalevia-CA1 (crofelemer delayed-release tablets), a natural, plant-based prescription product.



IMPORTANT SAFETY INFORMATION

For oral use in dogs only. Not for use in humans. Keep Canalevia®-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. **It is a violation of Federal law to use this product other than as directed in the labeling.**

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

Support Your Dog's Comfort During Chemotherapy Treatment



An estimated 6 million new cancer diagnoses are made in dogs each year.¹ Approximately 30% of dogs treated with chemotherapy will experience CID.²



Canalevia®-CA1 eases the burden of illness by providing a well-tolerated treatment for CID in dogs, improving the dog's comfort and quality of life.



Naturally and sustainably harvested from the sap of a medicinal tropical plant, the *Croton lechleri* tree.



How can Canalevia-CA1 help my dog?

Treating CID can improve the quality of life for dogs undergoing an already traumatic experience, reduce the chance of extra visits to your vet, and support your dog's ability to maintain control, which is important for management of your home and general living environment. **Importantly, treating CID in dogs can help prevent interruption in their chemotherapy treatment plan.**

What is the source of crofelemer, the natural active pharmaceutical ingredient in Canalevia-CA1?

Crofelemer is a natural product sustainably derived from the sap, or latex, of the Amazonian tree species *Croton lechleri*, which has a rich history of medicinal use by Indigenous peoples in the Western Amazon rainforests of South America. To learn more about the history of crofelemer, see [The Ethnobotanical Origins of Canalevia-CA1](#) section of this guide.



Extracting sap from a *Croton lechleri* tree in the Northwestern Amazon

What is chemotherapy?

Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells. Chemotherapy is most often used to treat cancer in people and dogs since cancer cells grow and multiply much more quickly than most other cells in the body. Due to the increasing number of chemotherapeutic agents being adopted by veterinarians and veterinary oncologists, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine.

What is chemotherapy-induced diarrhea (CID)?


For the most part, dogs receive human chemotherapeutic agents during treatment and suffer the same side effects as humans. Most chemotherapeutic agents target rapidly dividing cells, and effects on these cells within the gastrointestinal tract can lead to a variety of symptoms. Diarrhea caused by chemotherapy, referred to as chemotherapy-induced diarrhea (CID), is a common problem in canine cancer patients. CID can induce distress and suffering in sensitive animals like dogs. Severe or prolonged diarrhea can result in significant dehydration and hospitalization due to water loss.

Can CID result in the need to decrease, pause, or stop my dog's chemotherapy treatment?

Approximately 37% of dogs undergoing cancer treatment may have their chemotherapy reduced, changed, or discontinued due to diarrhea²—which can compromise the full benefit of the chemotherapy agent. Managing CID is important to help support the outcome of your dog's cancer treatment, and to help support your veterinarian's efforts to maintain your dog's chemotherapy treatment plan.

How does Canalevia-CA1 work?

CID occurs when excess fluids are secreted into your dog's gastrointestinal tract. Canalevia-CA1 treats CID by normalizing fluid influx into the dog's gastrointestinal tract.



How is Canalevia®-CA1 administered to dogs?

Administer one Canalevia-CA1 tablet orally twice daily for 3 days to dogs weighing up to 140 pounds. For dogs weighing more than 140 pounds, administer two tablets orally twice daily for 3 days. Tablets should be swallowed whole and should not be broken, crushed, or chewed. If the dose is chewed, one additional dose may be administered.

Can I administer Canalevia-CA1 to my dog at home?

Yes. Following consultation with your veterinarian, you may administer Canalevia-CA1 yourself to your dog at home.

Can I break or crush the Canalevia-CA1 tablet and put it in my dog's food?

No. Canalevia-CA1 tablets should be swallowed whole and should not be broken, crushed, or chewed. If your dog chews the dose, one additional dose may be administered.

If my dog vomits up the Canalevia-CA1 tablet, what do I do?

If your dog vomits up the Canalevia-CA1 tablet, one additional dose may be administered following consultation with your veterinarian.

How do I know if my dog is suffering from CID-related dehydration?

Diarrhea results from the secretion of excess fluids into your dog's intestines. Severe or prolonged diarrhea can result in significant dehydration and hospitalization due to water loss. After your dog has started chemotherapy, please contact your veterinarian if your dog develops watery diarrhea, becomes lethargic, quits eating, or has started vomiting.

Is Canalevia-CA1 available only by prescription?

Yes, Canalevia-CA1 is only available by prescription from licensed veterinarians in the U.S.

Have any other products received any type of approval from the FDA to treat CID in dogs?

Canalevia-CA1 is conditionally approved by the U.S. Food and Drug Administration (FDA) for the treatment of CID in dogs. **Canalevia-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA.**

Human products like Kaopectate or Pepto-Bismol are sometimes used to address CID in dogs, but using these over-the-counter treatments is discouraged because they contain aspirin products. Additionally, unlike Canalevia-CA1, human products like Imodium or Lomotil are opioids which can cause constipation.

What does "FDA conditional approval" mean?

Canalevia-CA1 is conditionally approved by the FDA under application number 141-552. Conditional approval status allows the product to be marketed and sold in the U.S. while Jaguar Animal Health continues to collect the substantial evidence of effectiveness required for a full approval from the FDA.

Where is Canalevia-CA1 available?

Any licensed veterinarian in the U.S. can prescribe Canalevia-CA1. If your dog is undergoing chemotherapy and suffering from diarrhea, please contact your veterinarian to find out if Canalevia-CA1 may be beneficial for your dog.

Where can I obtain information about Canalevia-CA1 to provide to my dog's veterinarian or veterinary oncologist?

Prescribing Information for veterinarians is available online at www.canalevia.com. Veterinarians and veterinary oncologists are also welcome to contact Jaguar Animal Health by phone at 877-787-3001 to speak with one of our staff veterinarians, or by email at info@canalevia.com.

Can I use Canalevia-CA1 for my cat suffering from CID?

No. Canalevia-CA1 is not approved by the FDA for use in cats nor has it been demonstrated to be safe or effective for treating CID in cats.

Contact Your Veterinarian About Canalevia-CA1



The Ethnobotanical Origins of Canalevia®-CA1



Crofelemer is the result of decades of research that began with the expertise of traditional healers of the Amazon Rainforest

The term ethnobotanical refers to the use of plants by Indigenous people in their everyday lives, including the use of plants for medicine. Crofelemer, the active pharmaceutical ingredient in Canalevia-CA1, is sustainably derived from the sap, or latex, of the Amazonian tree species *Croton lechleri*, which has a rich history of medicinal use by Indigenous peoples in the Western Amazon rainforests of South America. The tree produces a blood-red latex from which crofelemer is isolated and purified.

The latex of the *Croton lechleri* tree is commonly called “Sangre de drago” in Spanish, which translates to “Dragon’s blood” in English. Because the tree’s latex is one of the most widely used plant-derived medicines in the western hemisphere, extensive research has been conducted on the chemistry and pharmacology of *Croton lechleri* latex. The latex continues to be part of rural and urban traditional medicine in multiple countries, including Peru, Ecuador, and Bolivia. Traditional Indigenous healers have utilized the latex for centuries as an oral treatment for a variety of medical conditions, including diarrhea, stomach ulcers, coughs, and flu, and they apply the latex topically as a wound-healing agent for cuts, open sores, and for healing the gums after tooth extractions.

Additionally, crofelemer is the active ingredient in an FDA-approved antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult human patients with HIV/AIDS on antiretroviral therapy.

A Longstanding Commitment to Benefit Sharing & Sustainability

The *Croton lechleri* tree is rapidly growing and abundant in multiple countries in rainforest regions. We focus on the long-term sustainable management of the tree as part of our commitment to helping local communities conserve their natural resources while also earning income for the basic needs of their families, such as food, clothing, health care, and education. Our team members have practiced fair trade with our local and Indigenous partners for more than two decades, which has provided income-generating opportunities for individuals, communities, and families. Across Peru, large numbers of *Croton lechleri* trees have been planted following harvesting in collaboration with communities and small local businesses.

To learn more about Canalevia-CA1
for your dog suffering from
chemotherapy-induced diarrhea,
speak with your veterinarian or visit
www.canalevia.com



Since 2001, more than 800,000 *Croton lechleri* trees have been planted. For every 1 tree harvested at least 2 new trees are planted.



IMPORTANT SAFETY INFORMATION

For oral use in dogs only. Not for use in humans. Keep Canalevia®-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.


Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. **It is a violation of Federal law to use this product other than as directed in the labeling.**

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

(crofelemer delayed-release tablets)
125 mg
antidiarrheal

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. **It is a violation of Federal law to use this product other than as directed in the labeling.**

DESCRIPTION: CANALEVIA- CA1 (crofelemer delayed-release tablets) is an antidiarrheal, enteric-coated drug product for oral administration. CANALEVIA-CA1 contains 125 mg of crofelemer, a botanical drug substance that is derived from the red latex of *Croton lechleri* Müll. Arg. Crofelemer is an oligomeric proanthocyanidin mixture primarily composed of (+)-catechin, (–)-epicatechin, (+)-gallocatechin, and (–)-epigallocatechin monomer units linked in random sequence, as represented below. The average degree of polymerization for the oligomers ranges between 5 and 7.5, as determined by phloroglucinol degradation.



DOSAGE AND ADMINISTRATION: Administer 1 tablet orally twice daily for 3 days for dogs weighing ≤ 140 pounds. Administer 2 tablets orally twice daily for 3 days for dogs weighing >140 pounds. Tablets should not be broken, crushed, or chewed. If the tablet is chewed, one additional dose may be administered. Give with or without food.

WARNINGS: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans.

PRECAUTIONS: The safe use of CANALEVIA-CA1 has not been evaluated in dogs that are pregnant, lactating, or intended for breeding.

ADVERSE REACTIONS: In a masked, randomized study to support a reasonable expectation of effectiveness (CANA-001a) there was similar incidence of adverse events in dogs administered crotelemer (not commercial formulation) compared to control dogs administered a vehicle control. Crotelemer was administered orally twice a day for three days as enteric-coated beads containing 40 mg of the active ingredient. The vehicle control was enteric-coated beads without the active ingredient. The dogs had daily assessments for changes in attitude, hydration, appetite, and abdominal palpation. Table 1 shows the adverse reactions during CANA-001a study.

Adverse Reaction ¹	Crofelemer N = 29	Vehicle Control N = 32
Appetite decreased	7 (24%)	9 (28%)
Attitude decreased	5 (17%)	5 (16%)
Activity decreased	4 (14%)	4 (13%)
Dehydration ²	4 (14%)	5 (16%)
Abdominal palpation indicated pain ³	3 (10%)	5 (16%)
Vomiting	1 (3%)	2 (6%)

In an open-label pilot study (CANA-001b), 48 dogs were administered crofelemer (not commercial formulation) orally twice a day for three days. The adverse reactions included decreased appetite in 16/48 (33%) dogs, vomiting in 3 (6%) dogs, decreased activity in 3 dogs (6%), abdominal pain in 1 (2%) dog, and 1 (2%) dog had blood in feces.

Adverse Reaction	Crofelemer N = 134	Placebo N = 66
Vomiting	11 (8%)	1 (2%)
Decreased blood glucose ¹	10 (8%)	3 (5%)
Urinary system abnormality ²	10 (8%)	2 (3%)
Upper respiratory signs ³	7 (5%)	0 (0%)
Decreased blood calcium ⁴	5 (4%)	0 (0%)

Treatment block	Crofelemer N = 12	Vehicle Control N = 12
≤24 hours	2 (17%)	0 (0%)
>24 hours and ≤48 hours	2 (17%)	0 (0%)
>48 hours and ≤72 hours	5 (42%)	3 (25%)

Hematology findings related to CANALEVIA-CA1 included 3 dogs that had a decreased hematocrit (reference range 37.2-52%) at study end compared to acclimation: 1 male administered 27.2 mg/kg with hematocrit of 39.6% prior to



JAH 111-060 Rev 03/22